Ocuphire Pharma, Inc. and Opus Genetics have combined under the Opus Genetics name (Nasdaq: IRD). As a combined company, we are committed to building an innovative, efficient and sustainable clinical-stage ophthalmic biopharmaceutical company leading the development of transformative gene therapies for the treatment of inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders.
Company Details
- Employees
- 24
- Address
- Raleigh, Nc, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.OpusGtx.com
- HQ
- Raleigh, NC
Opus Genetics Questions
Opus Genetics's website is http://www.OpusGtx.com
Opus Genetics's LinkedIn profile is https://www.linkedin.com/company/opus-genetics
Opus Genetics has
24 employees.
View email and phone details for 24
employees at Opus Genetics.
Opus Genetics's industry is
Biotechnology Research
Opus Genetics's top competitors are
Beam Therapeutics,
Kriya Therapeutics, Inc.,
Recode Therapeutics,
Lexitas Pharma Services,
Atsena Therapeutics,
Yoltech Therapeutics,
Askbio Inc.,
Precision Biosciences, Inc.,
Ocugen,
Nanoscope Therapeutics Inc..
Opus Genetics's categories are Biotechnology Research
